By Adria Calatayud
PARIS (Dow Jones)–Sanofi wants to end the clinical development program for the drug candidate Tusamitamab Ravtansine. The reason is that a study in late-stage non-small cell lung cancer (NSCLC) in previously treated patients did not achieve the primary goal, the French pharmaceutical company said.
The decision was made after an independent data monitoring committee found that tusamitamab ravtansine monotherapy failed to achieve a primary goal of progression-free survival compared to docetaxel. The study had two main objectives: progression-free survival and overall survival. Only overall survival has improved.
Sanofi also said it will continue to explore the potential of tusamitamab-based antibody-drug conjugates and investigate the potential of certain molecules as biomarkers in various types of cancer.
Contact the author: [email protected]
DJG/DJN/uxd/kla
(END) Dow Jones Newswires
December 21, 2023 02:42 ET (07:42 GMT)
Selected leverage products on Sanofi
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Sanofi
The leverage must be between 2 and 20
Advertising